Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Michael I. Nishimura"'
Autor:
Nishant K. Singh, Jesus A. Alonso, Jason R. Devlin, Grant L. J. Keller, George I. Gray, Adarsh K. Chiranjivi, Sara G. Foote, Lauren M. Landau, Alyssa G. Arbuiso, Laura I. Weiss, Aaron M. Rosenberg, Lance M. Hellman, Michael I. Nishimura, Brian M. Baker
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
MHC restriction depicts CD4+ T cell activation by MHC-II and CD8A+ by MHC-I, but rare T cells with mismatched MHC restriction have been reported. Here the authors use crystallography to describe features of such a mismatched TCR-MHC interaction and i
Externí odkaz:
https://doaj.org/article/0743243588da4db7b9427d68ad78e7b9
Autor:
Xueliang Gao, Yongxia Wu, Joel M. Chick, Andrea Abbott, Baishan Jiang, David J. Wang, Susana Comte-Walters, Roger H. Johnson, Nathaniel Oberholtzer, Michael I. Nishimura, Steven P. Gygi, Anand Mehta, Denis C. Guttridge, Lauren Ball, Shikhar Mehrotra, Piotr Sicinski, Xue-Zhong Yu, Haizhen Wang
Publikováno v:
Cell Reports, Vol 42, Iss 4, Pp 112314- (2023)
Summary: Elucidating the mechanisms of resistance to immunotherapy and developing strategies to improve its efficacy are challenging goals. Bioinformatics analysis demonstrates that high CDK6 expression in melanoma is associated with poor progression
Externí odkaz:
https://doaj.org/article/d8061c0240544238ba7cf4290e1b4efe
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Adoptive T cell therapy with T cell receptor (TCR)-modified T cells has shown promise in treating metastatic melanoma and other malignancies. However, studies are needed to improve the efficacy and durability of responses of TCR-modified T c
Externí odkaz:
https://doaj.org/article/0d6455e91542435a9f8f3cd3c71292a6
Autor:
Tamson V. Moore, Gina M. Scurti, Matthew DeJong, Siao-Yi Wang, Annika V. Dalheim, Courtney R. Wagner, Kelli A. Hutchens, Jodi J. Speiser, Constantine V. Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D. Curti, Joseph I. Clark, Bernard A. Fox, Michael I. Nishimura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 352-363 (2021)
T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated seven metastatic melanoma patients with autologous T cells transduced to express a tyrosin
Externí odkaz:
https://doaj.org/article/89a5e7e4a04a46e287fbf116f56ea560
Autor:
Suzanne Quinn, Natasha Lenart, Victoria Dronzek, Gina M. Scurti, Nasheed M. Hossain, Michael I. Nishimura
Publikováno v:
Vaccines, Vol 10, Iss 3, p 457 (2022)
Immunotherapy is a beneficial treatment approach for multiple cancers, however, current therapies are effective only in a small subset of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy where T cells targeting the tumor cells are t
Externí odkaz:
https://doaj.org/article/a143d7add8e7460fbf251ae60183ed45
Autor:
Kendra C. Foley, Timothy T. Spear, David C. Murray, Kaoru Nagato, Elizabeth Garrett-Mayer, Michael I. Nishimura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 105-115 (2017)
T cell receptor (TCR)-gene-modified T cells for adoptive cell transfer can mediate objective clinical responses in melanoma and other malignancies. When introducing a second TCR, mispairing between the endogenous and introduced α and β TCR chains l
Externí odkaz:
https://doaj.org/article/3189595fbbd7476cb5193f7c6d87a5a8
Autor:
Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett-Mayer, Colleen A. Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres M. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li, David J. Cole
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-13 (2017)
Abstract Background Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus, we posit that DC-based immunotherapy, in conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is a promising approach
Externí odkaz:
https://doaj.org/article/24af04bf4a4248ecafa4d737c8c57263
Autor:
Cormac Cosgrove, Emilia R. Dellacecca, Michael I. Nishimura, I. Caroline Le Poole, Hans E. N. Bergmans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019)
Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In particular, the long-term consequences of
Externí odkaz:
https://doaj.org/article/145c95d215cc4b3fb69f8db492a7a925
Autor:
Dewen You, Junping Xin, Andrew Volk, Wei Wei, Rachel Schmidt, Gina Scurti, Sucha Nand, Eun-Kyoung Breuer, Paul C. Kuo, Peter Breslin, Ameet R. Kini, Michael I. Nishimura, Nancy J. Zeleznik-Le, Jiwang Zhang
Publikováno v:
Cell Reports, Vol 10, Iss 12, Pp 2055-2068 (2015)
Mutations and inactivation of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) are observed in 15%–25% of cases of human T cell acute lymphoblastic leukemia (T-ALL). Pten deletion induces myeloproliferative disorders (MPDs), acute m
Externí odkaz:
https://doaj.org/article/fbbe6516a419435696ed1b95c74a3386
Autor:
Laurent Muller, Patricia Simms, Chang-Sook Hong, Michael I. Nishimura, Edwin K. Jackson, Simon C. Watkins, Theresa L. Whiteside
Publikováno v:
OncoImmunology, Vol 6, Iss 8 (2017)
Tumor-derived exosomes (TEX) are ubiquitously present in the tumor microenvironment and plasma of cancer patients. TEX carry a cargo of multiple stimulatory and inhibitory molecules and deliver them to recipient cells, serving as a communication netw
Externí odkaz:
https://doaj.org/article/7994caddcfd545479c20609a4a4b9ccf